PL2195311T3 - Pochodne pirydynowe jako modulatory receptora S1P1/EDG1 - Google Patents
Pochodne pirydynowe jako modulatory receptora S1P1/EDG1Info
- Publication number
- PL2195311T3 PL2195311T3 PL08789611T PL08789611T PL2195311T3 PL 2195311 T3 PL2195311 T3 PL 2195311T3 PL 08789611 T PL08789611 T PL 08789611T PL 08789611 T PL08789611 T PL 08789611T PL 2195311 T3 PL2195311 T3 PL 2195311T3
- Authority
- PL
- Poland
- Prior art keywords
- receptor modulators
- pyridine derivatives
- edg1 receptor
- edg1
- pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2007053293 | 2007-08-17 | ||
| PCT/IB2008/053269 WO2009024905A1 (en) | 2007-08-17 | 2008-08-14 | Pyridine derivatives as s1p1/edg1 receptor modulators |
| EP08789611A EP2195311B1 (en) | 2007-08-17 | 2008-08-14 | Pyridine derivatives as s1p1/edg1 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2195311T3 true PL2195311T3 (pl) | 2011-08-31 |
Family
ID=40193868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08789611T PL2195311T3 (pl) | 2007-08-17 | 2008-08-14 | Pochodne pirydynowe jako modulatory receptora S1P1/EDG1 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8598208B2 (pl) |
| EP (1) | EP2195311B1 (pl) |
| JP (1) | JP5451614B2 (pl) |
| KR (1) | KR101541558B1 (pl) |
| CN (1) | CN102648198B (pl) |
| AR (1) | AR067977A1 (pl) |
| AT (1) | ATE502938T1 (pl) |
| AU (1) | AU2008290233B2 (pl) |
| BR (1) | BRPI0815190A2 (pl) |
| CA (1) | CA2695509A1 (pl) |
| CY (1) | CY1111830T1 (pl) |
| DE (1) | DE602008005770D1 (pl) |
| DK (1) | DK2195311T3 (pl) |
| ES (1) | ES2361463T3 (pl) |
| HK (1) | HK1144809A1 (pl) |
| HR (1) | HRP20110449T1 (pl) |
| MA (1) | MA31703B1 (pl) |
| MX (1) | MX2010001881A (pl) |
| MY (1) | MY153975A (pl) |
| NZ (1) | NZ583957A (pl) |
| PL (1) | PL2195311T3 (pl) |
| PT (1) | PT2195311E (pl) |
| RU (1) | RU2492168C2 (pl) |
| SI (1) | SI2195311T1 (pl) |
| TW (1) | TWI422373B (pl) |
| WO (1) | WO2009024905A1 (pl) |
| ZA (1) | ZA201001873B (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI392671B (zh) * | 2006-09-07 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 吡啶-４-基衍生物 |
| PL2069335T3 (pl) | 2006-09-08 | 2013-05-31 | Actelion Pharmaceuticals Ltd | Pochodne pirydyn-3-ylu jako środki immunomodulujące |
| EP2079734A1 (en) * | 2006-10-25 | 2009-07-22 | NeuroSearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| DK2125797T3 (da) * | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
| KR101615779B1 (ko) * | 2008-03-07 | 2016-04-26 | 액테리온 파마슈티칼 리미티드 | 면역조절제로서 피리딘-2-일 유도체 |
| KR101718639B1 (ko) | 2008-03-17 | 2017-03-21 | 액테리온 파마슈티칼 리미티드 | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 |
| SG175855A1 (en) * | 2009-05-04 | 2011-12-29 | Prometic Biosciences Inc | Substituted aromatic compounds and pharmaceutical uses thereof |
| RU2547098C2 (ru) | 2009-07-16 | 2015-04-10 | Актелион Фармасьютиклз Лтд | Производные пиридин-4-ила |
| WO2012098505A1 (en) | 2011-01-19 | 2012-07-26 | Actelion Pharmaceuticals Ltd | 2-methoxy-pyridin-4-yl derivatives |
| EP2844655A1 (en) | 2012-05-02 | 2015-03-11 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| MX350891B (es) | 2012-08-17 | 2017-09-22 | Actelion Pharmaceuticals Ltd | Proceso para la preparacion de (2z,5z)-5-(3-cloro-4-((r)-2,3-dihid roxipropoxi) bencilideno)-2-(propilimino)-3-(o-tolil) tiazolidin-4-ona y el intermediario usado en dicho proceso. |
| NZ713080A (en) | 2013-03-15 | 2020-06-26 | Idorsia Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
| HUE047646T2 (hu) | 2015-05-20 | 2020-05-28 | Idorsia Pharmaceuticals Ltd | Az (S)-3-{4-[5-(2-ciklopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi} -propán-1,2-diol vegyület kristályformája |
| US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
| WO2017004609A1 (en) | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Thiadiazole modulators of s1p and methods of making and using |
| WO2017004610A1 (en) | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Tercyclic s1p3-sparing, s1p1 receptor agonists |
| WO2017004608A1 (en) | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Oxadiazole modulators of s1p methods of making and using |
| EA201891644A1 (ru) | 2016-03-07 | 2019-04-30 | Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. | Антибактериальные соединения и их применение |
| TW201808906A (zh) | 2016-03-16 | 2018-03-16 | 拜耳作物科學股份有限公司 | 作為殺蟲劑之經取代吡啶化合物 |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| EP4211112A1 (en) * | 2020-09-11 | 2023-07-19 | PI Industries Ltd. | A process for the preparation of substituted pyridine compounds and intermediates thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3647809A (en) * | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| AU7686891A (en) | 1990-04-05 | 1991-10-30 | American National Red Cross, The | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
| US6423508B1 (en) | 1998-03-09 | 2002-07-23 | Smithkline Beecham Corporation | Polynucleotide sequences of human EDG-1c |
| NZ517221A (en) | 1999-08-19 | 2004-01-30 | Nps Pharma Inc | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| MXPA03007513A (es) | 2001-02-21 | 2004-07-30 | Nps Pharma Inc | Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato. |
| JP4709488B2 (ja) | 2002-01-18 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類 |
| EP1470137B1 (en) | 2002-01-18 | 2009-09-02 | Merck & Co., Inc. | Edg receptor agonists |
| WO2004035538A1 (en) | 2002-10-15 | 2004-04-29 | Merck & Co., Inc. | Process for making azetidine-3-carboxylic acid |
| US20060252741A1 (en) * | 2003-05-15 | 2006-11-09 | Colandrea Vincent J | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| CN1859908A (zh) | 2003-10-01 | 2006-11-08 | 默克公司 | 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物 |
| CA2547198A1 (en) * | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| MXPA06013912A (es) | 2004-05-29 | 2007-07-18 | 7Tm Pharma As | Ligandos del receptor de crth2 para usos medicinales. |
| CN101160285A (zh) | 2005-03-17 | 2008-04-09 | 辉瑞大药厂 | 适用于治疗疼痛的n-(n-磺酰氨基甲基)环丙烷甲酰胺衍生物 |
| AU2006239418A1 (en) | 2005-04-26 | 2006-11-02 | Neurosearch A/S | Novel oxadiazole derivatives and their medical use |
| CA2610310A1 (en) | 2005-06-08 | 2006-12-14 | Novartis Ag | Polycyclic oxadiazoles or isoxazoles and their use as s1p receptor ligands |
| WO2007001973A1 (en) | 2005-06-28 | 2007-01-04 | Astrazeneca Ab | New use |
| TWI404706B (zh) * | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| ES2335242T3 (es) * | 2006-01-24 | 2010-03-23 | Actelion Pharmaceuticals Ltd. | Derivados novedosos de piridina. |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| TWI392671B (zh) * | 2006-09-07 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 吡啶-４-基衍生物 |
| PL2069335T3 (pl) * | 2006-09-08 | 2013-05-31 | Actelion Pharmaceuticals Ltd | Pochodne pirydyn-3-ylu jako środki immunomodulujące |
| ES2393412T3 (es) * | 2006-09-21 | 2012-12-21 | Actelion Pharmaceuticals Ltd. | Derivados de fenilo y su uso como inmunomoduladores |
| NZ577111A (en) | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
| DK2125797T3 (da) * | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
| AU2008320374A1 (en) * | 2007-11-01 | 2009-05-07 | Actelion Pharmaceuticals Ltd | Novel pyrimidine derivatives |
| WO2009109907A1 (en) * | 2008-03-06 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel pyrimidine-pyridine derivatives |
| JP5411877B2 (ja) * | 2008-03-06 | 2014-02-12 | アクテリオン ファーマシューティカルズ リミテッド | ピリジン化合物 |
| KR101615779B1 (ko) * | 2008-03-07 | 2016-04-26 | 액테리온 파마슈티칼 리미티드 | 면역조절제로서 피리딘-2-일 유도체 |
| EP2262782B1 (en) * | 2008-03-07 | 2012-07-04 | Actelion Pharmaceuticals Ltd. | Novel aminomethyl benzene derivatives |
| PT2291080E (pt) | 2008-05-14 | 2015-10-30 | Scripps Research Inst | Novos modelamodeladores dos recetores da esfingosina fosfato |
| RU2547098C2 (ru) * | 2009-07-16 | 2015-04-10 | Актелион Фармасьютиклз Лтд | Производные пиридин-4-ила |
-
2008
- 2008-08-14 WO PCT/IB2008/053269 patent/WO2009024905A1/en active Application Filing
- 2008-08-14 BR BRPI0815190 patent/BRPI0815190A2/pt not_active IP Right Cessation
- 2008-08-14 RU RU2010109542/04A patent/RU2492168C2/ru not_active IP Right Cessation
- 2008-08-14 AU AU2008290233A patent/AU2008290233B2/en not_active Ceased
- 2008-08-14 MX MX2010001881A patent/MX2010001881A/es active IP Right Grant
- 2008-08-14 PL PL08789611T patent/PL2195311T3/pl unknown
- 2008-08-14 SI SI200830269T patent/SI2195311T1/sl unknown
- 2008-08-14 DK DK08789611.4T patent/DK2195311T3/da active
- 2008-08-14 ES ES08789611T patent/ES2361463T3/es active Active
- 2008-08-14 KR KR1020107005759A patent/KR101541558B1/ko not_active IP Right Cessation
- 2008-08-14 NZ NZ583957A patent/NZ583957A/en not_active IP Right Cessation
- 2008-08-14 DE DE602008005770T patent/DE602008005770D1/de active Active
- 2008-08-14 MY MYPI2010000684A patent/MY153975A/en unknown
- 2008-08-14 US US12/673,918 patent/US8598208B2/en not_active Expired - Fee Related
- 2008-08-14 AT AT08789611T patent/ATE502938T1/de active
- 2008-08-14 EP EP08789611A patent/EP2195311B1/en not_active Not-in-force
- 2008-08-14 JP JP2010520670A patent/JP5451614B2/ja not_active Expired - Fee Related
- 2008-08-14 CA CA2695509A patent/CA2695509A1/en not_active Abandoned
- 2008-08-14 PT PT08789611T patent/PT2195311E/pt unknown
- 2008-08-14 CN CN200880103070.2A patent/CN102648198B/zh not_active Expired - Fee Related
- 2008-08-15 TW TW097131346A patent/TWI422373B/zh not_active IP Right Cessation
- 2008-08-19 AR ARP080103611A patent/AR067977A1/es not_active Application Discontinuation
-
2010
- 2010-03-12 MA MA32693A patent/MA31703B1/fr unknown
- 2010-03-16 ZA ZA2010/01873A patent/ZA201001873B/en unknown
- 2010-12-03 HK HK10111281.3A patent/HK1144809A1/xx not_active IP Right Cessation
-
2011
- 2011-05-30 CY CY20111100521T patent/CY1111830T1/el unknown
- 2011-06-16 HR HR20110449T patent/HRP20110449T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1144809A1 (en) | Pyridine derivatives as s1p1/edg1 receptor modulators | |
| IL200911A0 (en) | Amino-pyridine derivatives as s1p1/edg1 receptor agonists | |
| ZA200906307B (en) | 8-oxy-quinoline derivatives as bradykinin B2 receptor modulators | |
| IL192657A (en) | Theophenic history as 1edg / 1p1s receptor agonists | |
| HK1134294A1 (en) | Thiophene derivatives as s1p1/edg1 receptor agonists | |
| PT2132209E (pt) | Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7) | |
| HK1170479A1 (en) | Pyridin-4-yl derivatives as s1p1/edg1 agonists | |
| HK1147968A1 (en) | Biphenylcarboxamide derivatives as hedgehog pathway modulators | |
| EP2344446A4 (en) | S1P RECEPTOR MODULATORS | |
| GB0701992D0 (en) | Grehlin Receptor Modulators | |
| EP2244577A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF M1 RECEIVER OF QUINOLIZIDINONE TYPE | |
| EP2312949A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF M1 N-HETEROCYCLIC RECEPTOR | |
| HK1167404A1 (en) | Benzothiadiazepine derivatives used as ampa and nmda receptor modulators ampa nmda | |
| EP2252151A4 (en) | POSITIVE ALLOSTERIC CHINOLIZIDINONE M1 RECEPTOR MODULATORS | |
| IL204786A0 (en) | Benzyl - cycloalkyl sphingosing 1 - phosphate receptor modulators | |
| ZA201004828B (en) | Cannabinoid receptor modulators | |
| EP2303275A4 (en) | STANDARD RECEPTOR MODULATORS | |
| EP2139489A4 (en) | Mineralocorticoid receptor modulators | |
| EP2340247A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF THE CHINOLIZIDINONE M1 RECEPTOR | |
| EP2268280A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF M1 RECEPTOR OF QUINOLIZIDINE | |
| EP2229167A4 (en) | MINERALCORTICOIDREZEPTORMODULATOREN | |
| ZA200806237B (en) | Cannibinoid receptor modulators | |
| ZA200907546B (en) | New progesterone receptor modulators | |
| HK1131787A1 (en) | Oxa-steroids derivatives as selective progesterone receptor modulators | |
| GB0717998D0 (en) | Canabinoid receptor modulators |